Roche lymphoma drug drives high remission rate, longer survival-study
December 10, 2017 at 09:00 AM EST
Dec 10 (Reuters) - An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment alone, according to data from a mid-stage trial released at a medical meeting on Sunday.